Search

Anton Dobrin

from New York, NY
Get Report
Connected to:
Ira R Dobrin, 58Joseph S Dobrin, 36Valeria M Dobrin, 113Yigal Dobriner, 73Catherine M Dobrinich, 86Daniel C Dobrinin, 41Jessica L Dobrinich, 41Michael K Dobrinic, 84Bruce E Dobrinska, 73Carisa M Dobrinski, 50

Anton Dobrin Phones & Addresses

  • New York, NY

Work

Company: Memorial sloan kettering cancer center Jul 1, 2015 Position: Graduate student

Education

Degree: Master of Science, Masters Specialities: Biotechnology, Biology

Skills

Research • Molecular Biology • Biochemistry • Science • Synthetic Biology • Biological Engineering • Experimental Design • Immunology • Histology • Programming

Industries

Biotechnology

Resumes

Resumes

Anton Dobrin Photo 1

Anton Dobrin

View page
Location:
New York, NY
Industry:
Biotechnology
Work:
Memorial Sloan Kettering Cancer Center
Graduate Student
Eth Zurich Feb 2014 - Jul 2015
Msc Student
University of Toronto May 2011 - Aug 2013
Project Student
University of Toronto Aug 2010 - Aug 2013
Scotiabank Information Commons Help Desk Advisor
Sickkids Foundation Sep 2010 - Apr 2011
Research Student
Education:
University of Toronto - University of Trinity College 2009 - 2013
Bachelors, Bachelor of Science, Genetics, Microbiology Northern Secondary School
Skills:
Research
Molecular Biology
Biochemistry
Science
Synthetic Biology
Biological Engineering
Experimental Design
Immunology
Histology
Programming

Publications

Us Patents

Non-Hla Restricted T Cell Receptors And Uses Thereof

View page
US Patent:
20200368283, Nov 26, 2020
Filed:
Aug 11, 2020
Appl. No.:
16/990185
Inventors:
- New York NY, US
Jorge A. Mansilla-Soto - Forest Hills NY, US
Justin Eyquem - New York NY, US
Anton Dobrin - New York NY, US
Assignee:
MEMORIAL SLOAN-KETTERING CANCER CENTER - New York NY
International Classification:
A61K 35/17
C07K 16/28
C07K 14/725
Abstract:
The presently disclosed subject matter provides methods and compositions for enhancing the immune response toward cancers and pathogens. It relates to novel designs of T cell receptors (TCRs) and engineered immunoresponsive cells comprising the same. The novel TCR binds to an antigen in an HLA-independent manner. In certain embodiments, the novel TCR provides enhanced sensitivity for a target gene having a low expression level.
Control profile
Anton Dobrin from New York, NY Get Report